Literature DB >> 27115380

Lyme Disease Serology.

Paul M Lantos1, Paul G Auwaerter2, Christina A Nelson3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27115380      PMCID： PMC5491346          DOI： 10.1001/jama.2016.4882

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  9 in total

1.  Neoplasms misdiagnosed as "chronic lyme disease".

Authors:  Christina Nelson; Sarah Elmendorf; Paul Mead
Journal:  JAMA Intern Med       Date:  2015-01       Impact factor: 21.873

2.  Collection and characterization of samples for establishment of a serum repository for lyme disease diagnostic test development and evaluation.

Authors:  Claudia R Molins; Christopher Sexton; John W Young; Laura V Ashton; Ryan Pappert; Charles B Beard; Martin E Schriefer
Journal:  J Clin Microbiol       Date:  2014-08-13       Impact factor: 5.948

3.  Comparison of lyme disease serologic assays and lyme specialty laboratories.

Authors:  Raymond J Dattwyler; Paul M Arnaboldi
Journal:  Clin Infect Dis       Date:  2014-09-02       Impact factor: 9.079

4.  Immunoblot interpretation criteria for serodiagnosis of early Lyme disease.

Authors:  S M Engstrom; E Shoop; R C Johnson
Journal:  J Clin Microbiol       Date:  1995-02       Impact factor: 5.948

Review 5.  Diagnosis of lyme borreliosis.

Authors:  Maria E Aguero-Rosenfeld; Guiqing Wang; Ira Schwartz; Gary P Wormser
Journal:  Clin Microbiol Rev       Date:  2005-07       Impact factor: 26.132

6.  Poor Positive Predictive Value of Lyme Disease Serologic Testing in an Area of Low Disease Incidence.

Authors:  Paul M Lantos; John A Branda; Joel C Boggan; Saumil M Chudgar; Elizabeth A Wilson; Felicia Ruffin; Vance Fowler; Paul G Auwaerter; Lise E Nigrovic
Journal:  Clin Infect Dis       Date:  2015-07-20       Impact factor: 9.079

7.  Empiric antibiotic treatment of erythema migrans-like skin lesions as a function of geography: a clinical and cost effectiveness modeling study.

Authors:  Paul M Lantos; R Jory Brinkerhoff; Gary P Wormser; Robert Clemen
Journal:  Vector Borne Zoonotic Dis       Date:  2013-10-09       Impact factor: 2.133

8.  Lyme disease testing by large commercial laboratories in the United States.

Authors:  Alison F Hinckley; Neeta P Connally; James I Meek; Barbara J Johnson; Melissa M Kemperman; Katherine A Feldman; Jennifer L White; Paul S Mead
Journal:  Clin Infect Dis       Date:  2014-05-30       Impact factor: 9.079

9.  Concerns regarding a new culture method for Borrelia burgdorferi not approved for the diagnosis of Lyme disease.

Authors:  Christina Nelson; Sally Hojvat; Barbara Johnson; Jeannine Petersen; Marty Schriefer; C Ben Beard; Lyle Petersen; Paul Mead
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2014-04-18       Impact factor: 17.586
  9 in total
  1 in total

1.  Acute lyme disease IgG N-linked glycans contrast the canonical inflammatory signature.

Authors:  Benjamin Samuel Haslund-Gourley; Stéphane Grauzam; Anand S Mehta; Brian Wigdahl; Mary Ann Comunale
Journal:  Front Immunol       Date:  2022-08-05       Impact factor: 8.786
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.